Novo's liraglutide gets CHMP nod for obesity

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said EMA's CHMP recommended marketing authorization of its Saxenda liraglutide for chronic weight management as an adjunct to diet and exercise in obese adults or in overweight adults with at least one co-morbidity.

CHMP based its recommendation on efficacy data from the Phase III SCALET trial, which evaluated 3 mg doses of the injectable drug in more than 5,000 patients with an initial Body Mass Index (BMI) >=30 kg/m^2 or 27-30 kg/m^2 plus co-morbidities. ...